{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T10:56:37Z","timestamp":1793876197166,"version":"4.7.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,12,20]],"date-time":"2013-12-20T00:00:00Z","timestamp":1387497600000},"content-version":"vor","delay-in-days":49,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.ahj.2013.07.012","type":"journal-article","created":{"date-parts":[[2013,10,2]],"date-time":"2013-10-02T17:42:48Z","timestamp":1380735768000},"page":"823-830.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":176,"title":["Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial"],"prefix":"10.1016","volume":"166","clinical-trial-number":[{"clinical-trial-number":"nct01179048","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Steven P.","family":"Marso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil R.","family":"Poulter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E.","family":"Nissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Nauck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Zinman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert H.","family":"Daniels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Pocock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William M.","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard M.","family":"Bergenstal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes F.E.","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lasse Steen","family":"Ravn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirstine Brown","family":"Frandsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan C.","family":"Moses","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B.","family":"Buse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2013.07.012_bb0005","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(11)60679-X","article-title":"National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants","volume":"378","author":"Danaei","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2013.07.012_bb0010","series-title":"National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants","year":"2007"},{"key":"10.1016\/j.ahj.2013.07.012_bb0015","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies","volume":"375","author":"Sarwar","year":"2010","journal-title":"Lancet"},{"issue":"Suppl. 1","key":"10.1016\/j.ahj.2013.07.012_bb0020","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.2337\/dc13-S011","article-title":"Standards of medical care in diabetes\u20142013","volume":"36","author":"American Diabetes Association","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ahj.2013.07.012_bb0025","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","article-title":"Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"35","author":"Inzucchi","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ahj.2013.07.012_bb0030","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2013.07.012_bb0035","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Gerstein","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2013.07.012_bb0040","series-title":"Guidance for Industry Diabetes Mellitus \u2014 Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes","year":"2008"},{"key":"10.1016\/j.ahj.2013.07.012_bb0045","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiol Rev"},{"key":"10.1016\/j.ahj.2013.07.012_bb0050","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2013.07.012_bb0055","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nrendo.2012.140","article-title":"GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus","volume":"8","author":"Meier","year":"2012","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.ahj.2013.07.012_bb0060","doi-asserted-by":"crossref","first-page":"906","DOI":"10.4158\/EP.17.6.906","article-title":"Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta-analysis of the liraglutide development program","volume":"17","author":"Henry","year":"2011","journal-title":"Endocr Pract"},{"key":"10.1016\/j.ahj.2013.07.012_bb0065","series-title":"Global guideline for type 2 diabetes","author":"International Diabetes Federation","year":"2005"},{"issue":"Suppl. 1","key":"10.1016\/j.ahj.2013.07.012_bb0070","first-page":"1","article-title":"American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus","volume":"13","author":"American Association of Clinical Endocrinologists","year":"2007","journal-title":"Endocr Pract"},{"key":"10.1016\/j.ahj.2013.07.012_bb0075","unstructured":"National Collaborating Center for Chronic Conditions and the Center for Clinical Practice. Clinical Guideline 87 Type 2 diabetes: the management of type 2 diabetes 2009."},{"key":"10.1016\/j.ahj.2013.07.012_bb0080","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2337\/dc08-9025","article-title":"Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"32","author":"Nathan","year":"2009","journal-title":"Diabetes Care"},{"issue":"Suppl. 1","key":"10.1016\/j.ahj.2013.07.012_bb0085","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.2337\/dc10-S011","article-title":"Standards of medical care in diabetes\u20142010","volume":"33","author":"American Diabetes Association","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ahj.2013.07.012_bb0090","series-title":"Points to consider on switching between superiority and non-inferiority","author":"European Agency for the Evaluation of Medicinal Products","year":"2000"},{"key":"10.1016\/j.ahj.2013.07.012_bb0095","series-title":"Design and analysis of non-inferiority trials","author":"Rothmann","year":"2011"},{"key":"10.1016\/j.ahj.2013.07.012_bb0100","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(10)60307-8","article-title":"Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial","volume":"375","author":"Pratley","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2013.07.012_bb0105","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/1755-5922.12000","article-title":"GLP-1 receptor agonists: effects on cardiovascular risk reduction","volume":"31","author":"Lorber","year":"2013","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.ahj.2013.07.012_bb0110","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(08)61246-5","article-title":"Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial","volume":"373","author":"Garber","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2013.07.012_bb0115","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1111\/j.1464-5491.2008.02484.x","article-title":"Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with type 2 diabetes","volume":"25","author":"Courreges","year":"2008","journal-title":"Diabet Med"},{"key":"10.1016\/j.ahj.2013.07.012_bb0120","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1111\/j.1464-5491.2012.03589.x","article-title":"Addition of liraglutide in patients with type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function","volume":"29","author":"Forst","year":"2012","journal-title":"Diabet Med"},{"key":"10.1016\/j.ahj.2013.07.012_bb0125","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1016\/j.jacc.2007.09.011","article-title":"Universal definition of myocardial infarction","volume":"50","author":"Thygesen","year":"2007","journal-title":"J Am Coll Cardiol"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000287031300450X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000287031300450X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:50:15Z","timestamp":1757569815000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000287031300450X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S000287031300450X"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2013.07.012","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2013.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Mosby, Inc.","name":"copyright","label":"Copyright"}]}}